Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets

Sosei Group CEO Shinichi Tamura Sosei Group’s unique drug discovery platform for G protein-coupled receptor (GPCR)-targeted compounds is attracting a growing list of big pharma companies, with CEO Shinichi Tamura stressing that small molecules are still “the high road” in...read more